Comparison of two assays for fibroblast growth factor (FGF)-23
Comparison of two assays for fibroblast growth factor (FGF)-23
复制标题
DOI：
10.1007/s00774-005-0625-4
复制
发表时间：
2005-11-01
影响因子：
3.3
通讯作者：
Fujita, T
中科院分区：
文献类型：
--
作者：
Ito, N;Fukumoto, S;Fujita, T
最近显示 FGF-23 参与多种低磷血症疾病的发生，包括 X 连锁低磷血症性佝偻病/骨软化症 (XLH) 和肿瘤诱发的佝偻病/骨软化症 (TIO)。 FGF-23 在 Arg(179) 和 Ser(180) 之间加工，只有全长 FGF-23 被证明会引起低磷血症。已报道了两种 FGF-23 测定方法。一种测定仅检测全长 FGF-23。相比之下，C 端测定可识别 FGF-23 的全长和加工后的 C 端片段。然而，使用这两种检测方法报告 TIO 和 XLH 患者循环 FGF-23 水平的结果存在差异。我们通过这两种检测同时测量了 13 名成人低磷血症性骨软化症患者和 29 名 XLH 患者的 FGF-23 水平。全长测定表明，所有骨软化症患者以及 29 名 XLH 患者中的 24 名患者的 FGF-23 均高于参考范围上限。然而，C 末端测定表明，13 名骨软化症患者中的 3 名和 29 名 XLH 患者中的 16 名 FGF-23 在参考范围内。此外，对于 FGF-23 在 C 端测定参考范围内的 XLH 患者，通过这些测定测量的 FGF-23 水平之间没有相关性。这些结果表明，C 端测定的 FGF-23 在参考范围内，并不排除全长 FGF-23 的增加。此外，由于 FGF-23 在大多数低磷血症患者中水平较高，因此这些结果支持 FGF-23 在 TIO 和 XLH 患者低磷血症的发生中起主要作用的观点。
FGF-23 was recently shown to be involved in the development of several hypophosphatemic diseases, including X-linked hypophosphatemic rickets/osteomalacia (XLH) and tumor-induced rickets/osteomalacia (TIO). FGF-23 is processed between Arg(179) and Ser(180), and only full-length FGF-23 was shown to cause hypophosphatemia. Two assays for FGF-23 have been reported. One assay detects only full-length FGF-23. In contrast, the C-terminal assay recognizes both full-length and processed C-terminal fragment of FGF-23. However, discrepant results concerning circulatory levels of FGF-23 in patients with TIO and XLH have been reported using these two assays. We simultaneously measured FGF-23 levels in 13 patients with adult-onset hypophosphatemic osteomalacia and 29 patients with XLH by these two assays. The full-length assay indicated that FGF-23 was above the upper limit of the reference range in all patients with osteomalacia and in 24 of 29 patients with XLH. However, the C-terminal assay in dicated that FGF-23 was within the reference range in 3 of 13 patients with osteomalacia and 16 of 29 patients with XLH. In addition, there was no correlation between FGF-23 levels measured by these assays in patients with XLH whose FGF-23 was within the reference range by C-terminal assay. These results indicate that FGF-23 within the reference range by C-terminal assay does not rule out an increase in full-length FGF-23. In addition, because FGF-23 was high in most of these hypophosphatemic patients, these results support the notion that FGF-23 plays a major role in the development of hypophosphatemia in patients with TIO and XLH.